Author

J. Mahajna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

H. Khamaisi· 2 shared J. Gopas· 2 shared A. Agbarya· 1 shared J. Moran-Gilad· 1 shared J. Zorea· 1 shared M. Elkabets· 1 shared R. Adawi· 1 shared R. Farah· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Khamaisi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivity.

Y. K. Carmi, A. Agbarya, H. Khamaisi, R. Farah, Y. Shechtman, R. Korobochka, J. Gopas, J. Mahajna

bioRxiv · Sep 24, 2023 · PreprintCancer Biology

Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells

Y. Koren Carmi, R. Adawi, H. Khamaisi, J. Gopas, J. Mahajna

This study identifies soluble factors from tumor-activated stromal cells that confer platinum chemoresistance to ovarian cancer cells and explores potential therapeutic strategies to restore sensitivity.

bioRxiv · Feb 24, 2023 · PreprintCancer Biology

TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer

J. Zorea, Y. Motro, R. Mazor, Y. Carmi, Z. Shulman, J. Mahajna, J. Moran-Gilad, M. Elkabets

This study identifies TRAF3 as a tumor-derived immune suppressor in ovarian cancer, showing its role in inhibiting B-cell infiltration and that microbiota presence is required for B-cell activation and tumor progression.

bioRxiv · Feb 9, 2023 · PreprintCancer Biology